Bispecific Antibody Market Forecast: Transforming Immunotherapy to 2033
This surge is largely driven by a rising demand for innovative treatments in oncology, infectious diseases, and autoimmune disorders, as well as groundbreaking advancements in antibody engineering. Powerful therapies, such as Blinatumomab and Catumaxomab, are leading the charge, while newer formats continue to emerge.